Caprihans India Ltd. (509486) (85)

Caprihans India Limited is one of the largest manufacturers of PVC Films in India and has got expertise of more than 35 years in this field. It manufacturers a wide variety of PVC films both Flexible & Rigid and also Sheets/Boards made from other polymers like ABS, PP, HDPE and Rigid PVC. The films are calendared while the sheets/Boards are extruded. Caprihans India Limited is a Public Limited company and became a part of EVC group in 1997. EVC was acquired by the INEOS group in 2001. The INEOS Films business was acquired by Bilcare in 2010. Caprihans India Limited is today part of Bilcares´ Solutions Division. The company has 4 calendaring lines, 3 extruder lines, 2 lamination and coating lines as also printing and embossing lines at its production units at Thane and Nasik, near Mumbai. It has an equity base of just Rs.13.13 crore that is supported by reserves of around Rs.99.93 crore which is 7.61 times higher than equity. It has a share book value of Rs.86.09 & price to book value ratio is just 0.97 which is highly impressive. The Promoters hold 71.93% (Foreign promoters hold 51%), DIIs hold 3.72% while the investing public holds 24.35% stake in the company. For 9MFY16, CIL has reported sales of Rs.190.63crore as against Rs.198.81crore in 9MFY15. Despite higher provisioning for income tax, profit after tax has gone up nicely by 26% to Rs.7.62crore (Net profit of 9MFY16 is higher than FY15 profit). 9MFY16 EPS stood at Rs.5.80. Script is trading at PE ratio of just 11. Company has paid 15% dividend for FY15. Script is looking highly attractive at current level for investment. Fallen crude price will increase company's profitability in coming quarters. Investors can buy this stock with stop loss of Rs.70. One the upper side it will zoom up to Rs.110 levels in medium term. Most of MNC stocks are trading above 25+ PE ratio so if CIL gets PE ratio of 25, its share price should be Rs.170. Its all-time high rate is Rs.143…

Comments

Best Buy For Monday Upper Circuit Expected TCI FINANCE

*Intraday & Short Term News For Monday* *Fii And Dii News* *TCI FINANCE LTD (501242 & NSE) (31)* Incorporated in 1973, TCI Finance Ltd (TCIFL) is a Non-Banking Finance Company (NBFC) registered with the RBI and engaged in the business of Inter-Corporate Deposits, investment in equities of bodies corporate etc. The Company was promoted by Mr. Mahendra Agarwal, who is also the Managing Director and CEO of Gati Ltd, a pioneer in express distribution and supply chain and promoted by TCFIL The Rs.2 paid-up share of Gati Ltd currently trades at Rs.113. TCIFL has one subsidiary - ITAG Business Solutions Ltd engaged in the business of Knowledge Process Outsourcing (KPO) in the domain of Intellectual Property Services. *It is co-promoter of GATI LTD. Company is holding 55,12,455 shares (5.09%) stake in GATI LTD. At CMP value of investments is around Rs.62.3crore. Equity is Rs.12.87crore. Thus value of investment works out to Rs.48.4 per share ...

Danlaw Technologies India Ltd: For multi-bagger gains (BSE Code: 532329) (CMP: Rs. 60.75) (FV: Rs.10)

The earnings season so far has been weak and worries over domestic growth continue to weigh on the market sentiment which has led the markets back on the downward path.. A value investor, however, need not worry about the broad markets as value stocks perform better and post good results. One such value-pick is Danlaw Technologies India Ltd. (DTIL). Company background: DTIL is the offshore technology and product development center of its parent company - Danlaw Incorporated, founded by Mr. Raju Dandu and Mr. Lloyd Lawrence in Michigan, USA in 1984. DTIL’s mission is to provide high quality services and products in Automotive Electronics, develop R&D driven Signal Processing technologies for communication and control, configure solutions and provide exceptional Information Technology (IT) services in the areas of education, health, banking and e-governance and provide world-class products and solutions for secured access through biometric access control technologies with intellige...

Some Opportunities Are left in Pharma Sector

Torrent Pharmaceuticals reported impressive 75% growth in revenues and profit in the first quarter of FY 2016. The sterling performance was driven by the launch of new product in the US market, which has limited competition at present. The focus is on the therapeutic segments of cardiovascular and CNS. There is presence in gastro-intestinal, diabetology, anti-infective, pain management, nephrology, oncology, gynecology and pediatric segments as well. The manufacturing plants for formulations and bulk drugs have been approved by authorities of several regulated and semi-regulated markets such as the US, the UK, Brazil, Germany, Australia and South Africa. Capacity will increase almost 100% once the new plant at Dahej in Gujarat becomes operational. The plant will be one of the largest pharmaceuticals manufacturing facilities in the country at a single location. The unit will primarily cater to the key regulated markets of the US and Europe. Approval from regulators such...

Value Research

Search This Blog